Wannan ƙaramar gwaji ne na ɗan Adam da aka raba cikin ƙungiyoyi biyu, ba gwajin dabbobi ba.
A cikinsa, haɗin rosemary, ashwagandha da luteolin da ake kira PB125 ya inganta alamar aikin jijiyoyin (endothelium) a manya bayan makonni biyu kacal, sannan ya hana raguwar wannan alama yayin kwana biyar na kwanciyar gado da aka ƙirƙira su. Ga cikakken bayani game da abin da binciken ya nuna da abin da ba ya nuna ba.
Menene PB125, ainihi?
PB125 maganin ganye ne mai kunna Nrf2. Nrf2 (nuclear factor erythroid‑2‑related factor 2) shine babban maɓalli na tsarin kariyar antioxidants na jiki. Haɗin ya ƙunshi sinadarai uku da aka samo daga tsirrai:
- Rosemary – carnosol da carnosic acid
- Ashwagandha – withaferin A
- Luteolin
Wannan shine tsarin da ake sayarwa a kasuwa da sunan Protandim NRF2 Synergizer. Manufar ƙungiyar bincike ita ce nuna cewa tsufa da rashin motsa jiki suna ƙara haɗarin cututtukan zuciya, inda wani ɓangare na hakan ke faruwa ne saboda raguwar aikin endothelium da ƙarancin Nrf2. Idan aka ƙara Nrf2, endothelium na iya aiki da kyau.
Yadda aka tsara gwajin
Binciken da Carlini da abokan aiki a Jami'ar Utah da VA na Salt Lake City suka jagoranta, an wallafa shi a Free Radical Biology and Medicine a 2026. An yi shi double‑blind, an raba mahalarta ba zato ba tsammani, sannan an yi amfani da placebo.
- Mahalarta: matasa 20 (maza 8, mata 12, shekara‑ta‑matsakaici 27 ± 7) da tsofaffi 24 (maza 12, mata 12, shekara‑ta‑matsakaici 67 ± 8)
- Hanyar magani: PB125 200 mg a rana ko placebo
- Ziyara uku: a farkon gwaji, bayan makonni biyu na ƙarin magani, da bayan ƙalubalen rashin amfani
- Kalubalen rashin amfani: kwana 5 na kwanciyar gado ga tsofaffi, ko makonni 2 na ɗaure ƙafar hannu ga matasa
- Abubuwan da aka auna: brachial (hannun) da popliteal (ƙafafu) arterial flow‑mediated dilation (FMD), yawan jini da motsi na ƙafa (vascular conductance), da serum superoxide dismutase (SOD) – enzyme antioxidant
FMD gwaji ne mara zafi da ake amfani da shi don auna yadda jijiyar ke faɗaɗa idan yawan jini ya ƙaru. Mafi girma na nufin ingantaccen aikin endothelium.
Sakamakon manya: tsofaffi sun amsa cikin makonni biyu
A cikin tsofaffi, makonni biyu na PB125 suka ƙara brachial FMD daga 2.8 ± 1.5 % zuwa 3.8 ± 1.3 % (p < 0.0001). Popliteal FMD kuma ya tashi daga 1.5 ± 1.5 % zuwa 2.3 ± 1.4 % (p = 0.033). Duk waɗannan ƙaruwa an kwatanta su da placebo.
Matasa ba su samu irin wannan haɓaka ba; FMD ba ta canza sosai ba a ƙungiyar da ta sha PB125 (duka p > 0.27). Wannan ya dace da ra'ayin cewa ƙarin yana haɓaka ne inda siginar Nrf2 ta ragu – matasa na iya riga suna da ingantaccen aikin endothelium, don haka babu wurin da za a inganta.
Gyarawa yayin kwanciyar gado: kariya, ba wai ƙaruwa ba
Kwanciyar gado gwaji ne mai tsanani da ke nuna abin da ke faruwa a asibiti ko lokacin raunuka. A nan, tsofaffi da ke shan PB125 sun ci gaba da riƙe matakin su idan aka kwatanta da placebo (duk p < 0.05):
- Brachial FMD: 3.8 ± 1.3 % → 3.6 ± 1.4 % (p = 0.543, ba a sami raguwar da ta kai ga muhimmanci ba)
- Popliteal FMD: 2.3 ± 1.4 % → 2.7 ± 1.4 % (p = 0.269)
- Leg vascular conductance: 1.1 ± 0.8 → 1.1 ± 1.5 (AUC, p = 0.530)
- Circulating SOD: 28.3 ± 7.2 → 28.6 ± 8.6 U/mL (p = 0.888)
Babu bayanin adadin ƙungiyar placebo a rubutun, amma bambancin da aka samu yana nuna cewa placebo ya fuskanci raguwar aikin jijiyoyi ko ya kasance a yanayi mafi muni. Takardar ta nuna cewa PB125 ya kiyaye aikin endothelium tare da ƙarfafa antioxidants.
Matasa: amfanin da ya fi takaitacce
Bayan makonni biyu na ɗaure ƙafa, matasa da ke shan PB125 sun kiyaye popliteal FMD (4.4 ± 2.8 % → 3.4 ± 1.8 %, p = 0.302 a cikin ƙungiya) idan aka kwatanta da placebo (p < 0.05). Wannan yana nufin ko da ba su samu haɓakar FMD a farkon ba, haɗin ya ba da kariya daga raguwar da rashin amfani ke haifarwa a ƙafar da aka ɗaure. Lura cewa canjin a cikin ƙungiya ba shi da muhimmanci a ƙididdiga; hujjar ainihi ta dogara ne akan bambancin da placebo.
Iyakoki da ya kamata ku sani
- Ƙananan samfur. Jimillar mahalarta 44 ne, an raba su zuwa ƙungiyoyi biyu da rukunai biyu, don haka kowanne rukuni ƙanana ne. Sakamakon na iya bayyana ƙarfi a ƙananan gwaje‑gwaje fiye da yadda zai kasance a manya.
- Alamomin wakili. FMD da yawan jini alamomin ne na aikin jijiyoyi. Binciken bai auna bugun zuciya, matakin cholesterol, ko wasu alamomin cuta ba.
- Tsawon lokaci kaɗan. Mako biyu na ƙarin ba su ba mu bayani game da amfanin ko aminci na dogon lokaci ba.
- Mabanbanta yanayin rashin amfani. Tsofaffi sun kwanta a gado, matasa kuma suka haɗa ƙafa; ba za a iya kwatanta ƙungiyoyin kai tsaye ba.
- Halayen mahalarta. Ba a bayyana ko mahalarta suna da cutar zuciya ko wasu cututtuka ba. Sakamakon na iya bambanta a cikin mutanen da ke da waɗannan cututtuka.
- Binciken guda ɗaya. Sai a sake maimaita shi a ƙungiyoyi masu zaman kansu. Marubutan sun ce babu rikice‑rikice a cikin bayanan, amma har yanzu shi ne gwaji ɗaya.
Abubuwan da za a iya amfani da su a aikace
Matsakaicin da aka gwada: 200 mg a rana na PB125. Takaitaccen bayani ba ya fayyace ko ana sha da safe ko da maraice, ko a tare da abinci; don haka ba za a iya samar da umarnin shan gama‑gari ba. Kada ku ɗauka cewa duk wani samfur na rosemary, ashwagandha ko luteolin da ke kasuwa ya daidai da wannan girma ko da wannan tsarin.
Wanene zai iya sha'awa: manya ƙasa da shekaru 60 da ke son fahimtar yadda hanyoyin jini ke tsufa, ko waɗanda ke fuskantar yanayin da ba za su iya motsi ba (misali, bayan tiyata ko a lokacin murmurewa). A cikin wannan gwaji, waɗannan ne rukunin da aka ga tasiri.
Wanene ba ya buƙatar shi: matasa masu lafiya da ba su da matsala a endothelium ba su nuna wani haɓakar FMD ba, don haka babu hujja cewa zai amfanar da su sai a yanayin ɗaure ƙafa.
Wanene ya kamata ya yi hankali ko ya guje shi: wannan shawara ce gaba ɗaya, ba daga takarda ba. Mutanen da ke ciki, masu shayarwa, masu matsalar thyroid ko hanta, masu amfani da magungunan hana garkuwar jiki, masu shan magungunan barci, ko masu amfani da magungunan hawan jini ko sukari su tuntuɓi likita kafin su ɗauki ƙarin. Ashwagandha na da ƙuntatawa ga wasu mutane, musamman masu matsalar thyroid.
Karshe
Wannan gwaji ya nuna alamar farfadowa mai ƙarfi – ƙara Nrf2 a cikin mutane na iya inganta kuma ya kare aikin endothelium. Koyaya, ba hujja ce da PB125 zai hana cutar zuciya ko ya hanzarta murmurewa daga kwanciyar gado ba. Za a buƙaci ƙarin gwaje‑gwaje masu girma da dogon lokaci tare da ainiƙan ƙididdiga na lafiyar zuciya kafin a yanke hukunci na ƙarshe.
